Science News
from research organizations

Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation

Date:
February 3, 2007
Source:
Journal of Clinical Investigation
Summary:
Treatment for skin cancer by infusion of tumor-reactive T cells requires patients to be pre-treated with agents that transiently decrease the number of immune cells (nonmyeloablative agents). A study in mice now indicates that pre-treatment with more intense immune cell--depleting strategies (known as myeloablative strategies) and a hematopoietic stem cell transplant enables infused tumor-reactive CD8+ T cells to increase in number more than pre-treatment with nonmyeloablative agents, and this correlates with increased tumor regression.
Share:
       
FULL STORY

Although treatment regimens involving the infusion of tumor-reactive T cells into patients with skin cancer (melanoma) have shown clinical benefit, there is plenty of room to improve the protocols to increase therapeutic benefit. Regimens currently being investigated in humans involve pre-treatment with agents that transiently decrease the number of immune cells (and that are known as nonmyeloablative agents), enabling the subsequently infused tumor-reactive T cells to increase in number in vivo.

In a study that appears in the February issue of the Journal of Clinical Investigation, Nicholas Restifo and colleagues from the National Institutes of Health show that in mice, pre-treatment with more intense immune cell--depleting strategies (known as myeloablative strategies) and a hematopoietic stem cell (HSC) transplantation enabled infused tumor-reactive CD8+ T cells to increase in number more than pre-treatment with nonmyeloablative agents.

Importantly, this increased expansion of the CD8+ T cell population correlated with increased tumor regression. Further analysis showed that it was the HSC transplantation, and not the increased immune cell depletion, that made the myeloablative agents more effective at inducing the infused tumor-reactive T cell population to expand and that it was the effector CD8+ T cell population, rather than the naïve T cell population, that expanded. This study has important implications for the future development of treatment regimens involving the infusion of tumor-reactive T cells into patients with melanoma.

In an accompanying commentary, Claudio Anasetti and James J. Mulé from the H. Lee Moffitt Comprehensive Cancer Center, Tampa, discuss the issues that are raised by these data and the implications that these issues have for the development of cell-based immunotherapies for cancer.


Story Source:

The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation." ScienceDaily. ScienceDaily, 3 February 2007. <www.sciencedaily.com/releases/2007/02/070201183043.htm>.
Journal of Clinical Investigation. (2007, February 3). Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation. ScienceDaily. Retrieved September 3, 2015 from www.sciencedaily.com/releases/2007/02/070201183043.htm
Journal of Clinical Investigation. "Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation." ScienceDaily. www.sciencedaily.com/releases/2007/02/070201183043.htm (accessed September 3, 2015).

Share This Page: